Learning From Exanta: AstraZeneca Ready For Phase III With ‘0837
Executive Summary
With its once-daily oral anticoagulant AZD0837 ready to move into Phase III, AstraZeneca is talking up the lessons it learned from its experience with the failed anticoagulantExanta (ximelagatran)
You may also be interested in...
AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
Backup compound to AstraZeneca’s failed Exanta is being investigated for a stability limitation; Crestor is the only branded statin to increase U.S. market share during 2008.
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.